New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 17, 2023 - AbbVie announced the FDA approval of Qulipta (atogepant), for the preventive treatment of migraine in adults.
Download PDF
Return to publications
